WG1
Pathophysiological mechanisms in atherosclerosis
Leaders
- Dimitris Kardassis
- Tijana Mitić
- Nuria Amigo
Objectives
- to identify current gaps and limitations in understanding atherosclerosis and discuss future directions of the research;
- to use multiomic approaches in specific cell line, organoids and preclinical models;
- to promote transfer of skills related to the basic studies in the interdisciplinary and intra-disciplinary manner.
Tasks & activities
- 1.1 Establishment of state-of-the-art and the knowledge gaps to be explored in the future;
- 1.2 Establishment of platform for exchange of workflows related to multiomics approaches, cell lines and preclinical models;
- 1.3 Development of the cell lines and preclinical models catalogue;
- 1.4 Selection of the best candidates for translation in the clinical settings based on unbiased and objective dialog;
- 1.5 Collaboration with private sector to promote commercialization of specific discoveries;
- 1.6 Management and coordination of WG1 meetings, STSMs and training schools, and monitoring of the progress of set objectives.
Deliverables
- D1.1 Joint review paper on state-of-the-art in atherosclerosis basic research models
- D1.2 Catalogue with specific cell lines and preclinical models available within the Action (updated during the Action)
- D1.3 Tech note summarizing hands-on experience in experimental workflows with relevant cell lines and preclinical models
- D1.4 Consensus paper on the best experimental models for ASCVD
- D1.5 Joint scientific papers on novel pathological mechanisms in atherosclerosis (based on the work during STSMs)
WG2
Personalized models for clinical applications in ASCVD
Leaders
- Alberico Catapano
- Luis Masana
- Liv Tybjærg Nordestgaard
Objectives
- to identify main obstacles for personalized approach to CVD management;
- to use multiomics approaches in well-defined large cohorts;
- to promote transfer of knowledge related to clinical practice in CVD management.
Tasks & activities
- 2.1 Encouraging dialog between basic and clinical scientist to understand each other needs and potentials;
- 2.2 Development of the integrative database based on multiomics analysis to help stratify disease severity between large cohorts;
- 2.3 Collaboration with clinics to explore real-life experience with developed tools;
- 2.4 Management and coordination of WG2 meetings, STSMs and training schools, and monitoring of the progress of set objectives.
Deliverables
- D2.1 Joint review paper on state-of-the-art of omics and ML/AI in ASCVD diagnostic and treatment
- D2.2 Integrative cohort database (updated during the Action);
- D2.3 Consensus paper on the best multiomics and ML/AI approaches in ASCVD risk stratification;
- D2.4 Joint scientific papers on novel predictive markers for ASCVD (based on work during STSMs);
- D2.5 Position paper on novel paradigms in personalized ASCVD strategies based on multiomics approach.
WG3
Standardization and harmonization of research
Leaders
- Marie Mardal
- David de Gonzalo Calvo
- Fabio Trindade
Objectives
- to form action plan with recommendations for research workflows;
- to establish guidelines for pre-analytical, analytical and post-analytical phase of omic targets;
- to lead inter-laboratory harmonization;
- to lead development of internal and external quality assurance materials;
- to promote Knowledge exchange related to harmonization and standardization.
Tasks & activities
- 3.1 Establishment of recommendations of research workflows through intra/inter-disciplinary cooperation;
- 3.2 Development of guidelines for pre-analytical, analytical and post-analytical phase;
- 3.3 Coordination of harmonization through inter-laboratory ring trials;
- 3.4 Collaboration with industry to explore development of quality assurance materials;
- 3.5 Management and coordination of WG3 meetings, STSMs and training schools, and monitoring of the progress of set objectives.
Deliverables
- D3.1 Tech note summarizing hands-on experience on preanalytical and analytical validation of DNA/RNA based biomarkers;
- D3.2 Joint scientific papers summarizing results of ring trials;
- D3.3 Consensus paper on standardization of omics markers;
- D3.4 Guidelines for pre-analytical, analytical and post-analytical validation of omics markers
WG4
Data integration and ML/AI
Leaders
- Aleksandra Gruca
- Artemis Hatzigeorgiou
- Baiba Vilne
Objectives
- to standardize pipelines and protocols for data pre-processing;
- identify limitations in current implementations and new ways of management;
- identify optimal state-of-the-art ML methodologies for construction of multiomic models in clinical use;
- provide researchers the ability to deploy ML models of their data with minor knowledge of the field enabling them to focus on their primary study;
- contribute in the ASCVD research by making ML accessible to researchers.
Tasks & activities
- 4.1 Develop pipelines for data pre-processing;
- 4.2 Appropriate transformation of the data for the ML models;
- 4.3 Design and development of the ML algorithms and software tools as great help for better disease stratification;
- 4.4 Utilization of multiple features selection procedures and isolation of the most consistent;
- 4.5 Automated hyperparameter tuning for each ML model, with comparisons between accuracy evaluation metrics;
- 4.6 create robust visualizations and reports for validation accuracy of the models and result interpretation.
Deliverables
- D4.1 Joint review paper on state-of-the-art in big data integration;
- D4.2 Consensus paper on the best ML/AI pipelines for data integration in ASCVD;
- D4.3 Personalized ASCVD prevention model based on multiomics data integration.
WG5
Dissemination and communication
Leaders
- Georgios Kararigas
- Brooke Wolford
- Zulema Rodriguez Hernandez
Objectives
- to develop online dissemination/communication tools;
- to reach stakeholders outside the Action;
- to coordinate publishing activities within the Action;
- to organise annual network meetings;
- to raise awareness onto CVD amongst the general population.
Tasks & activities
- 5.1 Development of online promotion tools (website and social channels, etc.);
- 5.2 Coordination of the development of a detailed database of all participants within the Action;
- 5.3 Coordination of publishing activities among WGs;
- 5.4 Coordination of the organisation of annual network meetings;
- 5.5 Support communication with NGOs and patients’ representative organisations.
Deliverables
- D5.1 Website and social media promotion tools;
- D5.2 Webinar series;
- D5.3 Promotional infosheets/booklets on current ASCVD risk, prevention and treatment strategies, primarily designed for the general population;
YRI
YRI Committee
Purpose
Members
- Nuria Amigo
- Liv Tybjærg Nordestgaard
- Fabio Trindade
- Baiba Vilne
- Brooke Wolford
- Zulema Rodríguez Hernández
- Ignacio Fernando Hall
- Melody Chemaly
- Christina Pagiatakis